Abstract

http://ssrn.com/abstract=1356530
 
 

Citations (4)



 
 

Footnotes (240)



 


 



An Aggregate Approach to Antitrust: Using New Data and Rulemaking to Preserve Drug Competition


C. Scott Hemphill


Columbia University - Law School

2009

Columbia Law Review, 2009
Columbia Law and Economics Working Paper No. 347

Abstract:     
This Article examines the “aggregation deficit” in antitrust: the pervasive lack of information, essential to choosing an optimal antitrust rule, about the frequency and costliness of anticompetitive activity. By synthesizing available information, the present analysis helps close the information gap for an important, unresolved issue in U.S. antitrust policy: patent settlements between brand-name drug makers and their generic rivals. The analysis draws upon a new dataset of 143 such settlements.

Due to the factual complexity of individual brand-generic settlements, important trends and arrangements become apparent only when multiple cases are examined collectively. This aggregate approach provides valuable information that can be used to set enforcement priorities, select a substantive liability standard, and identify the proper decisionmaker. The analysis uncovers an evolution in the means - including a variety of complex side deals - by which a brand-name firm can pay a generic firm to delay entry. The Article proposes two solutions for such anticompetitive behavior, one doctrinal and one institutional: a presumption of (illegal) payment where a side deal is reached contemporaneously with delayed entry, and an expanded role for agencies, to gather and synthesize nonpublic information regarding settlements, and potentially to engage in substantive rulemaking. The aggregate approach also reveals the shortcomings of antitrust enforcement where, as here, firms can exploit regulatory complexity to disguise collusive activity.

Number of Pages in PDF File: 60

Keywords: agency, antitrust, drug, Chevron, Cipro, exclusion payment, FTC, Federal Trade Commission, generic drugs, Hatch-Waxman, paragraph IV, pay for delay, patent, pharmaceutical, regulation, reverse payment, rulemaking, Schering, settlement, Sherman Act, tamoxifen

Accepted Paper Series


Download This Paper

Date posted: March 11, 2009 ; Last revised: December 28, 2013

Suggested Citation

Hemphill, C. Scott, An Aggregate Approach to Antitrust: Using New Data and Rulemaking to Preserve Drug Competition (2009). Columbia Law Review, 2009; Columbia Law and Economics Working Paper No. 347. Available at SSRN: http://ssrn.com/abstract=1356530

Contact Information

C. Scott Hemphill (Contact Author)
Columbia University - Law School ( email )
435 West 116th Street
New York, NY 10025
United States
Feedback to SSRN


Paper statistics
Abstract Views: 2,658
Downloads: 581
Download Rank: 24,626
Citations:  4
Footnotes:  240

© 2014 Social Science Electronic Publishing, Inc. All Rights Reserved.  FAQ   Terms of Use   Privacy Policy   Copyright   Contact Us
This page was processed by apollo3 in 0.610 seconds